丙肝投药治疗(治疗丙肝用药)
防走失,电梯直达安全岛报人刘亚东A
来源:知识分子
作者:刘楚
参考文献:(上下滑动可浏览)
[1]https://www.businesswire.com/news/home/20211001005189/en/Merck-and-Ridgeback%E2%80%99s-Investigational-Oral-Antiviral-Molnupiravir-Reduced-the-Risk-of-Hospitalization-or-Death-by-Approximately-50-Percent-Compared-to-Placebo-for-Patients-with-Mild-or-Moderate-COVID-19-in-Positive-Interim-Analysis-of-Phase-3-Study
[2]https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
[3] https://mp.weixin.qq.com/s/GBDOQU76OIf4398vwguSoA
[4] https://www.nature.com/articles/s41594-021-00651-0
[5]https://www.washingtonpost.com/health/2021/11/04/covid19-pill-merck-molnupiravir-approval-uk/
[6]https://www.barrons.com/articles/merck-covid-pill-risks-51633398722